R. Martin Chavez
Angel Investor @ NMS Capital
New York, United States
R. Martin Chavez is a Series A investor at NMS Capital in New York focused on Health Care and Biotechnology. Marty Chavez is executive vice president and chief financial officer of The Goldman Sachs Group, Inc. He is a member of the Management Committee, Firmwide Capital Committee, Firmwide Risk Committee and Steering Committee on Regulatory Reform. Marty is also a member of the Firmwide Hispanic/Latino Network and the Lesbian, Gay, Bisexual andTransgender Network.Marty first joined Goldman Sachs in 1993 in the J. Aron Currency and Commodities Division, where he was a senior energy strat until 1997. He returned to the firm as a managing director in Investment Banking Division Strats in 2005, becoming global co-head of Securities Division Strats and then global co-chief operating officer of the Equities Franchise. Prior to assuming his current role, Marty was chief information officer, responsible for the Technology Division and jointly responsible with divisional leadership for the firm’s global strategists. He was named partner in 2006.Prior to first joining the firm, Marty was co-founder and chief technology officer of Quorum Software Systems from 1989 to 1993. From 1997 to 2000, he was global head of energy derivatives at Credit Suisse Financial Products. In 2000, Marty co-founded Kiodex, Inc. and was chairman and chief executive officer until 2004.Marty serves on the Harvard Board of Overseers and is a Fellow of the New York Academy of Medicine.Marty earned a PhD in Medical Information Sciences from Stanford University in 1990, an SM in Computer Science from Harvard University in 1985, and an AB, magna cum laude, in Biochemical Sciences from Harvard College in 1985.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries R. Martin Chavez invests in
Stages R. Martin Chavez invests in
Countries R. Martin Chavez invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (36%)
- Biotechnology 4 (29%)
- Machine Learning 3 (21%)
- Artificial Intelligence 3 (21%)
- Software 2 (14%)
Stage
- Series A 7 (50%)
- Seed 3 (21%)
- Pre-Seed 2 (14%)
- Private Equity 2 (14%)
Country
- United States 11 (79%)
- United Kingdom 2 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The company specializes in developing AI research agents that streamline knowledge workflows. | $43.5M / Series A / May 14, 2025 | ||
| Somite is a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies. | $47M / Series A / May 13, 2025 | ||
| AI technology company in stealth mode. | $2M / Pre-Seed / Oct 29, 2023 | ||
| Hypervolt is a vertically integrated energy transition company, creating a new wave of grid management technologies, and empowering adoption of EVs and decarbonisation of transportation in the mobility sector. | $8M / Series A / Sep 30, 2023 | ||
| Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | ||
| Hebbia's core software application, Matrix, ingests unstructured information from corporate document repositories, financial filings, expert transcripts, and virtual data rooms to index facts into auditable knowledge charts. The system utilizes multi-agent orchestration to automate sequential administrative processes, enabling users toconstruct comparison tables, generate investment research reports, and track compliance documentation. | $30M / Series A / Jul 01, 2022 | ||
| Beepboop is a gamified language learning platform enabling educators to easily engage hundreds of students online in interactive exercises called Drills that empower students to speak the language they’re learning. During a Drill, our educators become stars using their charisma and compassion to guide large groups of students in spoken challenges.Our AI enables educators to provide better feedback and engage larger class sizes. | $260K / Pre-Seed / Mar 01, 2022 | ||
| PostEra uses machine learning to close the design-make-test loop of drug discovery and reduce our clients' cycle times. We are currently leading an international team of scientists to find a COVID antiviral via on open science initative. Consider contributing your expertise to the initiative here: https://postera.ai/covid | $24M / Series A / Jan 11, 2022 | ||
| Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | $40M / Series A / Jan 12, 2021 | ||
| DataFleets is a privacy-preserving data engine that unifies distributed data for rapid access, agile analytics, and automated compliance. The platform provides data scientists and developers with a "data fleet" that allows them to create analytics, ML models, and applications on highly sensitive data sets without ever having explicitaccess to the data. Each data fleet has easy-to-use APIs, and under-the-hood they ensure data protection using advances in federated computation, transfer learning, encryption, and differential privacy.DataFleets helps organizations to overcome the struggle between data privacy and innovation by helping them maintain data protection standards for compliance while accelerating data science initiatives. | $4.5M / Seed / Oct 26, 2020 | ||
| See all 14 investments → | |||
Co-Investors
About NMS Capital
NMS Capital is a private investment firm specializing in strategic equity investments and leveraged buyouts of lower middle market companies.
NMS Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Donza Worden
Vice President
|
|||
Martin Chavez
Co-Founder & Managing Partner
|
|||
Michael Lehman
Vice President
|
|||
Neal Monga
Vice President
|
|||
Noel Jeon
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does R. Martin Chavez invest in?
R. Martin Chavez invests primarily in Health Care, Biotechnology and Machine Learning startups, most often at Series A and Seed stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact R. Martin Chavez?
Public channels for R. Martin Chavez include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did R. Martin Chavez last invest?
The most recent investment recorded for R. Martin Chavez closed in May 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
